journal article·2024-11-20

Reactive Oxygen Species Responsive Supramolecular Prodrug Eyedrops for the Treatment of Choroidal Neovascularization

Shuting Xu, Jia Li, Kaiqi Long, Weiping Wang

Nano Letters· Volume 24· Issue 46
Publisher page

Abstract

Choroidal neovascularization (CNV) represents a hallmark of neovascular fundus diseases, including age-related macular degeneration and diabetic retinopathy. Traditional eyedrops have encountered formidable challenges in treating CNV, primarily due to their extremely poor intraocular bioavailability and potential adverse off-target effects. Herein, an ocular-permeable supramolecular prodrug eyedrop (Di-DAS/P-PCD) has been developed for the on-demand delivery of antiangiogenic agents in the oxidative microenvironment of CNV. The eyedrop nanoformulation is composed of cell-penetrating peptide-modified PEGylated cyclodextrin (P-PCD) and reactive oxygen species (ROS)-sensitive antiangiogenic dasatinib prodrug Di-DAS. In a laser-induced CNV mouse model, daily instillation of Di-DAS/P-PCD has achieved remarkable penetration into the choroid and significantly suppressed CNV growth while exhibiting a good biocompatibility profile. Our results highlight the potential of the supramolecular prodrug eyedrops as a versatile approach for the targeted treatment of CNV and other neovascular eye disorders.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cerebral Venous Sinus Thrombosis · Glaucoma and retinal disorders · Retinal Diseases and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China

Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong, China

Funding

Excellent Young Scientists Fund

References (62)

Show source-provided references
1. 10.1016/S2214-109X(20)30489-710.1016/S2214-109X(20)30489-7 ↗
2. 10.1007/s00125-002-0990-710.1007/s00125-002-0990-7 ↗
3. 10.1258/jrsm.2009.08029810.1258/jrsm.2009.080298 ↗
4. 10.1186/s40942-017-0084-910.1186/s40942-017-0084-9 ↗
5. 10.1016/j.ajo.2003.09.04210.1016/j.ajo.2003.09.042 ↗
6. 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H ↗
7. 10.1002/adhm.20230462610.1002/adhm.202304626 ↗
8. 10.1038/eye.2016.21610.1038/eye.2016.216 ↗
9. 10.1038/s41572-021-00265-210.1038/s41572-021-00265-2 ↗
10. 10.1186/s12951-023-01992-210.1186/s12951-023-01992-2 ↗
11. 10.1016/j.jconrel.2018.06.02310.1016/j.jconrel.2018.06.023 ↗
12. 10.3390/pharmaceutics1107032110.3390/pharmaceutics11070321 ↗
13. 10.1016/j.addr.2023.11486410.1016/j.addr.2023.114864 ↗
14. 10.1038/eye.2013.10710.1038/eye.2013.107 ↗
15. 10.1016/j.survophthal.2010.08.00610.1016/j.survophthal.2010.08.006 ↗
16. 10.18632/oncotarget.1763410.18632/oncotarget.17634 ↗
17. 10.3390/antiox1207137910.3390/antiox12071379 ↗
18. 10.1038/s41572-021-00265-210.1038/s41572-021-00265-2 ↗
19. 10.1016/j.mcna.2021.01.00310.1016/j.mcna.2021.01.003 ↗
20. 10.1038/s41467-019-11262-110.1038/s41467-019-11262-1 ↗
21. 10.1111/ceo.1383410.1111/ceo.13834 ↗
22. 10.1016/j.jconrel.2010.04.01910.1016/j.jconrel.2010.04.019 ↗
23. 10.1016/j.nantod.2010.06.01110.1016/j.nantod.2010.06.011 ↗
24. 10.1002/advs.20230198510.1002/advs.202301985 ↗
25. 10.1038/nrclinonc.2009.12910.1038/nrclinonc.2009.129 ↗
26. 10.3892/ijmm.20.1.11310.3892/ijmm.20.1.113 ↗
27. 10.1016/S0092-8674(00)80664-910.1016/S0092-8674(00)80664-9 ↗
28. 10.1016/S1097-2765(00)80221-X10.1016/S1097-2765(00)80221-X ↗
29. 10.1016/j.addr.2019.05.01010.1016/j.addr.2019.05.010 ↗
30. 10.1016/j.jconrel.2014.06.04410.1016/j.jconrel.2014.06.044 ↗
31. 10.1016/j.biomaterials.2022.12149310.1016/j.biomaterials.2022.121493 ↗
32. 10.1016/j.addr.2023.11472110.1016/j.addr.2023.114721 ↗
33. 10.1016/j.jconrel.2014.05.03110.1016/j.jconrel.2014.05.031 ↗
34. 10.7150/thno.5906510.7150/thno.59065 ↗
35. 10.1002/adma.20220969010.1002/adma.202209690 ↗
36. 10.1021/acsnano.7b0042910.1021/acsnano.7b00429 ↗
37. 10.2353/ajpath.2010.09087810.2353/ajpath.2010.090878 ↗
38. 10.1016/S0891-5849(98)00115-410.1016/S0891-5849(98)00115-4 ↗
39. 10.3390/antiox1106113310.3390/antiox11061133 ↗
40. 10.1039/D0NR03710A10.1039/D0NR03710A ↗
41. 10.1038/nrd318710.1038/nrd3187 ↗
42. 10.1158/0008-5472.CAN-08-113110.1158/0008-5472.CAN-08-1131 ↗
43. 10.1186/1471-2407-13-26710.1186/1471-2407-13-267 ↗
44. 10.1038/nprot.2013.13510.1038/nprot.2013.135 ↗
45. 10.1167/iovs.63.9.1110.1167/iovs.63.9.11 ↗
46. 10.1038/s41467-019-08690-410.1038/s41467-019-08690-4 ↗
47. 10.1038/nprot.2013.13510.1038/nprot.2013.135 ↗
48. 10.1038/nature0448210.1038/nature04482 ↗
49. 10.3390/biom1306098210.3390/biom13060982 ↗
50. 10.3390/biomedicines1111304410.3390/biomedicines11113044 ↗
51. 10.1007/s10456-007-9067-z10.1007/s10456-007-9067-z ↗
52. 10.1016/j.jconrel.2020.01.05710.1016/j.jconrel.2020.01.057 ↗
53. 10.1016/j.phrs.2019.10460910.1016/j.phrs.2019.104609 ↗
54. 10.1038/nrclinonc.2009.13010.1038/nrclinonc.2009.130 ↗
55. 10.1016/j.biomaterials.2021.12068210.1016/j.biomaterials.2021.120682 ↗
56. 10.1016/j.ijpharm.2021.12059110.1016/j.ijpharm.2021.120591 ↗
57. 10.1002/adma.20200243910.1002/adma.202002439 ↗
58. 10.1002/anie.20220948410.1002/anie.202209484 ↗
59. 10.1002/advs.20240421810.1002/advs.202404218 ↗
60. 10.1038/s41467-021-21071-010.1038/s41467-021-21071-0 ↗
61. 10.1016/j.jddst.2015.10.01110.1016/j.jddst.2015.10.011 ↗
62. 10.1016/j.ccr.2022.21491910.1016/j.ccr.2022.214919 ↗